<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320564</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046320</org_study_id>
    <secondary_id>LUC-2017-001</secondary_id>
    <nct_id>NCT03320564</nct_id>
  </id_info>
  <brief_title>Infiltration Effect on SUV</brief_title>
  <official_title>A Study to Assess the Impact of Moderate/Significant Infiltrations on the Standardized Uptake Values of Target Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lucerno Dynamics, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A widely used semi-quantitative parameter to assess tumor status is the standardized uptake
      value (SUV). SUV estimation accuracy can be impacted by many variables. Today there still
      exists a significant amount of variability in PET/CT results in test and re-test studies.
      This variability can be introduced by instrumentation and subject-specific factors.
      Variability reduces image quality and increases the required changes in tumor quantification
      to reflect real tumor response or progression.

      PET/CT scanning process requires that the entire net injected dose of radiolabeled tracer is
      administered intravenously as a bolus. The quality and quantification of a PET/CT image is
      highly dependent on the uptake of radiolabeled tracer. Boellaard et al. have indicated
      infiltrations could potentially underestimate SUV measurements by as much as 50%.
      Infiltrations and obstructions are not uncommon.

      Recent studies using a novel QA/QC tool (LaraTM System) for the radiotracer injection process
      revealed that current means to detect infiltration do not completely identify all
      infiltrations/obstructions. Since infiltrations may not be visible in the standard field of
      view (FOV) and since the impact of a peripheral circulatory obstruction may not be visible
      even if an injection site is in the FOV, it is possible for reading and treating physicians
      to be unaware that a patient's image and quantification has been impacted. Additionally, when
      current means do detect an infiltration, they under-represent the severity because they are
      not capturing that infiltrations often resolve during the uptake period. As a result,
      infiltrations or obstructions may cause SUV inaccuracy and could adversely impact staging and
      tumor assessments.

      The purpose of this study will be to characterize the impact of moderate or greater
      infiltrations on standardized uptake values. Patients experiencing a moderate or greater
      infiltration on a routine clinical PET scan will be invited to return for a repeat scan with
      injection performed by specially trained personnel to reduce the risk of repeat infiltration.
      The two scans will be compared to assess for changes in tumor uptake intensity.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment slow due to improved extravasation rate.
  </why_stopped>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients with a moderate or greater infiltration on a routine F-18 FDG PET will be invited to return for a repeat scan.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Reader will not be informed which scan was infiltrated.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SUVpeak of Target Lesions Between Infiltrated and Non-infiltrated Scans</measure>
    <time_frame>Baseline scan and follow up scan within 7 days</time_frame>
    <description>Target lesions selected as per PERCIST criteria. These criteria require more space than allowed to explain. Reference J Nucl Med 2009; 50: 122S-150S. DOI: 10.2967/jnumed.108.057307</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Metabolic Tumor Volume of Target Lesions Between Infiltrated and Non-infiltrated Scans</measure>
    <time_frame>7 days</time_frame>
    <description>Metabolic tumor volume to be measured using threshold defined in PERCIST criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Total Lesion Glycolysis of Target Lesions Between Infiltrated and Non-infiltrated Scans</measure>
    <time_frame>7 days</time_frame>
    <description>Total lesion glycolysis is calculated for the same metabolic tumor volume as Outcome 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Estimated Tumor Stage or Predicted Response to Therapy Between Infiltrated and Non-infiltrated Scans</measure>
    <time_frame>7 days</time_frame>
    <description>Response is defined per PERCIST criteria</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Dose Response Relationship, Drug</condition>
  <arm_group>
    <arm_group_label>Infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat F-18 FDG PET</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>F-18 FDG PET</intervention_name>
    <description>Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.</description>
    <arm_group_label>Infiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with solid tumors undergoing PET/CT scan who have at least one measurable
             target lesion and sustain a moderate or greater infiltration.

        Exclusion Criteria:

          -  Subjects unwilling or unable to tolerate a repeat PET/CT scan.

          -  Subjects with meaningful medical intervention between PET/CT scans that would likely
             impact SUV.

          -  Subjects with follow up injection infiltrations that would likely impact the SUV.

          -  Pregnant patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane C Masters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Baptist Health, Department of Radiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Osman MM, Muzaffar R, Altinyay ME, Teymouri C. FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements. Front Oncol. 2011 Nov 16;1:41. doi: 10.3389/fonc.2011.00041. eCollection 2011.</citation>
    <PMID>22655246</PMID>
  </reference>
  <reference>
    <citation>Silva-Rodríguez J, Aguiar P, Sánchez M, Mosquera J, Luna-Vega V, Cortés J, Garrido M, Pombar M, Ruibal A. Correction for FDG PET dose extravasations: Monte Carlo validation and quantitative evaluation of patient studies. Med Phys. 2014 May;41(5):052502. doi: 10.1118/1.4870979.</citation>
    <PMID>24784399</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <results_first_submitted>February 18, 2019</results_first_submitted>
  <results_first_submitted_qc>March 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2019</results_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>injections, intravenous</keyword>
  <keyword>fluorodeoxyglucose F-18</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03320564/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03320564/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infiltration</title>
          <description>Repeat F-18 FDG PET
F-18 FDG PET: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infiltration</title>
          <description>Repeat F-18 FDG PET
F-18 FDG PET: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Lara TAC score</title>
          <description>Range of values is -infinity to infinity. Less than 0 is considered non-extravasated. Greater than 1000 is considered at least moderate extravasation Larger values indicate greater severity of extravasation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1104" spread="NA">Single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in SUVpeak of Target Lesions Between Infiltrated and Non-infiltrated Scans</title>
        <description>Target lesions selected as per PERCIST criteria. These criteria require more space than allowed to explain. Reference J Nucl Med 2009; 50: 122S-150S. DOI: 10.2967/jnumed.108.057307</description>
        <time_frame>Baseline scan and follow up scan within 7 days</time_frame>
        <population>Up to 5 target lesions measured per participant (4 for this subject) with mean and standard deviation reported below.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration</title>
            <description>Repeat F-18 FDG PET
F-18 FDG PET: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SUVpeak of Target Lesions Between Infiltrated and Non-infiltrated Scans</title>
          <description>Target lesions selected as per PERCIST criteria. These criteria require more space than allowed to explain. Reference J Nucl Med 2009; 50: 122S-150S. DOI: 10.2967/jnumed.108.057307</description>
          <population>Up to 5 target lesions measured per participant (4 for this subject) with mean and standard deviation reported below.</population>
          <units>SUV (dimensionless)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Metabolic Tumor Volume of Target Lesions Between Infiltrated and Non-infiltrated Scans</title>
        <description>Metabolic tumor volume to be measured using threshold defined in PERCIST criteria</description>
        <time_frame>7 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Total Lesion Glycolysis of Target Lesions Between Infiltrated and Non-infiltrated Scans</title>
        <description>Total lesion glycolysis is calculated for the same metabolic tumor volume as Outcome 2</description>
        <time_frame>7 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Estimated Tumor Stage or Predicted Response to Therapy Between Infiltrated and Non-infiltrated Scans</title>
        <description>Response is defined per PERCIST criteria</description>
        <time_frame>7 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All subjects assessed from enrollment to study closure. For the subject with data recorded, approximately 5 months between enrollment and study closure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infiltration</title>
          <description>Repeat F-18 FDG PET
F-18 FDG PET: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Subject hospitalized 4 days after initial PET scan due to abdominal pain ongoing prior to enrollment, attributed to the malignancy that prompted the PET scan. Repeat scan had not yet happened at this time.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early study termination due to slow subject accrual with resulting sample size too small for analysis. This was mainly due to improvement in injection techniques and lower than expected extravasation rate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shane Masters</name_or_title>
      <organization>Wake Forest Baptist Health</organization>
      <phone>336-716-3590</phone>
      <email>smasters@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

